How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,649 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Thyroid Cancer Treatment (PDQ®): Patient Version

Thyroid Cancer Treatment (PDQ®): Patient Version Thyroid Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002 (...) -. Search term Thyroid Cancer Treatment (Adult) (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: May 23, 2018. This PDQ cancer information summary has current information about the treatment of adult thyroid cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards

2018 PDQ - NCI's Comprehensive Cancer Database

62. Sorafenib (Nexavar) for Metastatic Progressive Differentiated Thyroid Carcinoma

the treating physician’s armamentarium. This is a patient population in whom there may be a role for treatment with sorafenib but where there is presently limited evidence supporting its use. pCODR Initial Clinical Guidance Report – Sorafenib (Nexavar) for Differentiated Thyroid Cancer pERC Meeting: April 16, 2015 © 2015 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW 10 4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT One patient advocacy group, Thyroid Cancer Canada (TCC), provided input on sorafenib (Nexavar (...) by patients out of pocket, or which require lengthy processes for public and private insurance to secure approval for the expense. In summary, both respondents stated that they felt very lucky to have been given the opportunity to participate in the clinical trial for the drug, and felt that the benefits of the medication greatly outweighed any negative impact of the side effects. pCODR Initial Clinical Guidance Report – Sorafenib (Nexavar) for Differentiated Thyroid Cancer pERC Meeting: April 16, 2015 ©

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

63. Anti-Thyroid Peroxidase Antibodies in the General Population

limited to English language documents published between January 1, 2010 and April 7, 2015. Internet links were provided, where available. The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article. Anti-Thyroid Peroxidase Antibodies in the General Population 2 SELECTION CRITERIA One reviewer screened citations and selected studies based (...) technology assessments, systematic reviews, meta-analyses, or randomized controlled trials were identified. Additional references of potential interest are provided in the appendix. OVERALL SUMMARY OF FINDINGS One evidence-based guideline 1 was identified regarding the measurement of anti-thyroid peroxidase antibodies in the general population. The European Thyroid Association guideline 1 for the management of subclinical hypothyroidism recommends that for thyroid antibody testing, initially raised serum

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

64. Thyroid disease patient reacts to ‘insulting’ Women’s Health magazine piece

Thyroid disease patient reacts to ‘insulting’ Women’s Health magazine piece Thyroid disease patient reacts to 'insulting' Women's Health magazine piece - HealthNewsReview.org Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical (...) thinking about health care interventions. And those will be still be alive on the site for a couple of years. 6093 Posts Menu May 7, 2018 Thyroid disease patient reacts to ‘insulting’ Women’s Health magazine piece Posted By Categories Tags Gary Schwitzer is the founder & publisher of HealthNewsReview.org. He estimates he’s been telling stories of patient harm from misleading media for more than 30 years. He tweets as @garyschwitzer. This is just one little story about one woman reacting to one magazine

2018 HealthNewsReview

65. Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. (PubMed)

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. Background: Thyroid hormones (THs) exert a strong influence on mammalian lipid metabolism at the systemic and hepatic levels by virtue of their roles in regulating circulating lipoprotein, triglyceride (TAG), and cholesterol levels, as well as hepatic TAG storage and metabolism. These effects are mediated by intricate sensing and feedback systems that function at the physiological (...) , metabolic, molecular, and transcriptional levels in the liver. Dysfunction in the pathways involved in lipid metabolism disrupts hepatic lipid homeostasis and contributes to the pathogenesis of metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD) and hypercholesterolemia. There has been strong interest in understanding and employing THs, TH metabolites, and TH mimetics as lipid-modifying drugs. Summary: THs regulate many processes involved in hepatic TAG and cholesterol metabolism

2019 Thyroid

66. Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases

, not recruiting First Posted : August 16, 2016 Last Update Posted : March 30, 2018 Sponsor: National Taiwan University Hospital Information provided by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: Clinical and subclinical thyroid disease is usually used to describe patients with mild symptoms correlated to hyperthyroid or hypothyroid state. Therapeutic decision for clinical and subclinical thyroid dysfunction should be considered individually (...) . But long term outcome for treatment of such functional and structural thyroid diseases had not been recorded delicately in Taiwan. Further investigations should be observed in the future.The purpose of this study is aiming for early prevention and detection the potential risk factors for thyroid diseases in Taiwan. Condition or disease Thyroid Diseases Detailed Description: Clinical and subclinical thyroid disease is usually used to describe patients with mild symptoms correlated to hyperthyroid

2016 Clinical Trials

67. Thyroid Cancer Screening (PDQ®): Health Professional Version

Thyroid Cancer Screening (PDQ®): Health Professional Version Thyroid Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002 (...) -. Search term Thyroid Cancer Screening (PDQ®) Health Professional Version PDQ Screening and Prevention Editorial Board . Published online: March 6, 2019. Created: August 29, 2017 . This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about thyroid cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health

2017 PDQ - NCI's Comprehensive Cancer Database

68. Technologies scoping report 22: In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies?

. Only one small trial of L-T4 treatment in patients with thyroid function tests within the reference range was identified. Across a battery of tests, clinical benefit of treatment was identified only in a test which assesses memory for non-verbal visual stimuli. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Hormone Replacement Therapy; Hormone Replacement Therapy; Humans; Hypothyroidism; Thyroid Hormones Language Published English Country of organisation Scotland (...) Technologies scoping report 22: In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies? In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies? In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies? Thompson L Record Status

2014 Health Technology Assessment (HTA) Database.

69. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

but a normal free T4. 3,8,9 It represents a com- pensatedstate inwhichincreasedTSH output isrequired tomain- tain normal circulating thyroid hormone levels. An elevated serum TSH is a sensitive indicator of some degree of thyroid fail- ure, and there is a clear inverse relationship with free T4 levels. The term implies that patients should be asymptomatic, although symptoms are dif?cult to assess, especially in patients in whom thyroid function tests have been checked because of nonspeci?c complaints (...) have persistent symptoms which can be related to the disease and L-T4 therapy 2/+00 Is there a biological rationale for persistent complaints in L-T4-treated hypothyroid patients? ETA Suggested explanations for persistent symptoms in L-T4-treated hypothyroid patients despite normalization of serum TSH, include awareness of a chronic disease, presence of associated autoimmune diseases, thyroid autoimmunity per se (independent of thyroid function), and inadequacy of L-T4 treatment to restore

2015 British Thyroid Association

70. Management of Thyroid Cancer

with thyroid cancer 61 15 Thyroid cancer in childhood 64 16 Pathology reporting, grading and staging of thyroid cancers 16.1 General principles 65 16.2 Pathology report 65 16.3 Pathological staging 65 16.4 Staging protocol 65 16.5 Summary of thyroid cancer types 65 17 Medullary thyroid cancer 17.1 Presentation 69 17.2 Initial investigations of patients with suspected or con? rmed MTC 70 17.3 Treatment 70 17.4 Adjuvant therapies 71 17.5 Pathology 72 17.6 Follow-up for MTC 73 17.7 Investigation of persistent (...) 21.3 Screening 86 21.4 Diagnosis and referral 86 21.5 Summary of treatment of thyroid cancer 87 21.6 Follow-up 88 Appendices 1. Assay methodology 89 2. Recognition of MEN3 (MEN2B) 94 3. Search methodology 95 4. Patient information 97 Patient support groups 97 Websites with useful information for patients 97 Lea? ets for patients 1. The thyroid gland and thyroid cancer – tests and treatment 99 2. Information for patients being investigated for thyroid lumps 102 3. Surgery for thyroid Cancer 104 4

2014 British Thyroid Association

71. Downregulation of miR-486-5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing (PubMed)

Downregulation of miR-486-5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing Abnormal expression of microRNA (miR) is associated with the occurrence and progression of various types of cancers, including papillary thyroid carcinoma (PTC). In the present study, the aim was to explore miR‑486‑5p expression and its role in PTC, as well as to investigate the biological function of its potential target genes. The expression levels of miR‑486‑5p and its (...) clinicopathological significance were examined in 507 PTC and 59 normal thyroid samples via The Cancer Genome Atlas (TCGA). Subsequently, the results were validated using data from Gene Expression Omnibus (GEO) and ArrayExpress. Receiver operating characteristic and summary receiver operating characteristic curves were used to assess the ability of miR‑486‑5p in distinguishing PTC from normal tissue. Furthermore, potential miR‑486‑5p mRNA targets were identified using 12 prediction tools and enrichment analysis

Full Text available with Trip Pro

2018 Molecular medicine reports

72. The Oral Microbiota is Associated With Autoimmune Thyroiditis

of Harbin Medical University Information provided by (Responsible Party): First Affiliated Hospital of Harbin Medical University Study Details Study Description Go to Brief Summary: Autoimmune thyroiditis (AITD) mainly includes Hashimoto's thyroiditis (HT) and Grave's disease (GD). Studies have shown that autoimmune thyroiditis is closely related to microbial disorders such as autoimmune thyroiditis However, there is no report on the relationship between oral microecology and autoimmune thyroiditis (...) thyroid function changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid function measured by Immunohistochemistry Other Outcome Measures: Serum thyroid related antibodies changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid related antibodies measured by Immunohistochemistry Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your

2018 Clinical Trials

73. The diagnostic and prognostic significance of long noncoding RNAs expression in thyroid cancer: A systematic review and meta-analysis.

The diagnostic and prognostic significance of long noncoding RNAs expression in thyroid cancer: A systematic review and meta-analysis. Thyroid cancer (TC) is the most common malignant endocrine-related cancer with an increasing trend worldwide. Therefore, it's in urgent need to find new markers for prognosis and diagnosis. Many long noncoding RNAs (lncRNAs) have been reported to be aberrantly expressed in TC, and may serve as biomarkers. Therefore, we performed this meta-analysis (...) : 0.70-0.87). Meanwhile, their sensitivity and specificity were 0.74 (95% CI: 0.59-0.85) and 0.81 (95% CI: 0.73-0.88) respectively, when used to differentiate patients with lymph node metastasis (LNM) from without LNM. The summary receiver operator characteristic curve (sROC) showed that lncRNAs could be considered as valuable diagnostic markers for distinguishing TC patients from the normal (AUC = 0.84) and TC patients with LNM from TC patients without LNM (AUC = 0.85).In summary, our meta-analysis

2018 Pathology, research and practice

74. Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

. Patients with intolerable toxicity to MKIs that meet the prior inclusion criteria and experience disease progression by RECIST v1.1 after stopping therapy may be included. Cohort 3: Patients with locally advanced or metastatic anaplastic thyroid cancer regardless of prior therapy. No prior therapy with immune check point inhibitors is allowed. No limitation of number of prior therapies. Life expectancy >3 months Adequate normal organ and marrow function as defined below: a) Haemoglobin ≥9.0 g/dL. b (...) Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2018 Clinical Trials

75. Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients

Identifier: NCT03757637 Recruitment Status : Not yet recruiting First Posted : November 29, 2018 Last Update Posted : November 29, 2018 See Sponsor: National Taiwan University Hospital Information provided by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: Background: Despite the good prognosis of patients with differentiated thyroid carcinomas (DTC), the diagnosis of cancer, fear of cancer recurrence and its side effects might still bring (...) help us better understanding DTC patients' impacts and care needs. The comparison of three groups of intervention will also help us to identify the best model to decrease distress and enhance life function for them. Condition or disease Intervention/treatment Phase Differentiated Thyroid Cancer Other: NLSCP Other: ICT supported HAP Not Applicable Detailed Description: Phase I is a cross-sectional survey study (first year) with the specific aims to examine the current status of physical distress

2018 Clinical Trials

76. Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD

, the percentage of those who did not reach the target of lipid-lowering therapy (LDL-C>1.8mmol/L) is usually higher than that in population with normal thyroid function. The present study aims to randomly compare two lipid-lowering therapeutic strategies (statins only vs. statins combined with thyroid hormone supplement). Condition or disease Intervention/treatment Phase Dyslipidemia Subclinical hypothyroïdism Statin ASCVD Drug: Pitavastatin and placebo Drug: Pitavastatin and levothyroxine Not Applicable (...) is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group. Outcome Measures Go to Primary Outcome Measures : Change of LDL-C levels [ Time Frame: Baseline and 6-month. ] Absolute change value of serum LDL-C levels between the baseline and 6-month assessment. Secondary Outcome Measures : Changes of non-LDL lipid levels (TC, TG, HDL-C, non-HDL-C) [ Time Frame: Baseline and 6-month

2018 Clinical Trials

77. Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Posted : February 8, 2019 See Sponsor: H. Lee Moffitt Cancer Center and Research Institute Information provided by (Responsible Party): H. Lee Moffitt Cancer Center and Research Institute Study Details Study Description Go to Brief Summary: Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI). The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (...) Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

78. A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

. ClinicalTrials.gov Identifier: NCT03573960 Recruitment Status : Recruiting First Posted : June 29, 2018 Last Update Posted : March 11, 2019 See Sponsor: Eisai Inc. Information provided by (Responsible Party): Eisai Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC). Condition or disease Intervention/treatment Phase Thyroid Neoplasms Drug (...) A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

79. Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ]

androgens and steroids are one of multiple factors provoked to be involved in pathogenesis of acne . Thyroid hormones have steroid like action that have many regulatory functions in many body organ functions including skin and pilosebaceous unit. Furthermore, subtle thyroid dysfunction was shown to have a role in many disease conditions. Thyroid hormone action on sebaceous glands is unclear. In hypothyroid states, sebocytes exhibit reduced rates of secretion that increases with thyroxine administration (...) , fast method for the determination of severity of acne, and it requires no special equipment and is relatively cost-effective. Its personal and interpersonal differences is low and it was first used by Doshi and his colleagues in 1997 in USA . To the best of knowledge, little is published about thyroid dysfunction in acne female patients of different age categories and correlating thyroid function with other important patient and acne variables as body mass index (BMI) , age (starting from 16 years

2018 Clinical Trials

80. Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Co.,Ltd Information provided by (Responsible Party): Suzhou Zelgen Biopharmaceuticals Co.,Ltd Study Details Study Description Go to Brief Summary: Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC). Condition or disease Intervention/treatment Phase Differentiated Thyroid Cancer Drug: Donafenib Drug: Placebo Phase 3 Detailed Description: This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases (...) Donafenib in 131I-Refractory Differentiated Thyroid Cancer Donafenib in 131I-Refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Donafenib in 131I-Refractory

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>